This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Bristol Myers' (BMY) Zeposia Fails Crohn's Disease Study
by Zacks Equity Research
Patients treated with Bristol Myers' (BMY) Zeposia in a phase III study for Crohn's disease did not achieve disease remission.
BMYPositive Net Change PFENegative Net Change ABBVPositive Net Change ADMAPositive Net Change
biotechs medical pharmaceuticals
Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus
by Zacks Equity Research
Kodiak (KOD) reports a wider-than-expected loss for fourth-quarter 2023. The company provides updates regarding its pipeline development plans.
VNDAPositive Net Change ANIPPositive Net Change ADMAPositive Net Change KODPositive Net Change
biotechs earnings
Stock Market News for Apr 1, 2024
by Zacks Equity Research
U.S. stock markets closed mixed on Thursday to end a fascinating first quarter of 2024.
MRNANegative Net Change
biotechs
2 Top Biotech Buyout Candidates
by Andrew Rocco
The resurgence of biotech stocks in recent months marks a promising trend for investors, fueled by a favorable market condition. Strategist Andrew Rocco divulges two biotech stocks with innovative drug pipelines that offer investors the potential to cash in on lucrative buyout opportunities
NVONegative Net Change LLYPositive Net Change IBBPositive Net Change VKTXPositive Net Change XBIPositive Net Change MDGLPositive Net Change
biotechnology biotechs pharmaceuticals
Moderna (MRNA) Posts Pipeline Progress, Secures Blackstone Funding
by Zacks Equity Research
Moderna (MRNA) posts data on three experimental vaccines and intends to advance them to late-stage studies. It also secures $750 million in funding from Blackstone to advance its influenza program.
MRNANegative Net Change ANIPPositive Net Change ADMAPositive Net Change GLPGPositive Net Change
biotechs medical messenger-rna vaccines
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
by Zacks Equity Research
Apogee (APGE) surges 95.6% in a month after reporting positive interim results from its phase I study for APG777 to treat AD. The company plans to initiate a phase II study for the same indication.
ACETPositive Net Change ADMAPositive Net Change FGENNegative Net Change APGEPositive Net Change
biotechnology biotechs medical pharmaceuticals
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.
VNDAPositive Net Change ADMAPositive Net Change SNDXPositive Net Change MORPositive Net Change
biotechs
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
by Kinjel Shah
While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.
AZNPositive Net Change JNJNegative Net Change NVONegative Net Change MRKNegative Net Change ABBVPositive Net Change
biotechs pharmaceuticals
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
by Ekta Bagri
Praxis Precision Medicines, Inc. (PRAX) and Viking Therapeutics, Inc. (VKTX) gain from positive study updates.
REGNPositive Net Change MRNANegative Net Change VKTXPositive Net Change PRAXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
by Zacks Equity Research
Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.
ACETPositive Net Change ADMAPositive Net Change AKBAPositive Net Change FGENNegative Net Change
biotechnology biotechs medical pharmaceuticals
Viking (VKTX) Up 17% on Encouraging Oral Obesity Drug Data
by Zacks Equity Research
Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.
RHHBYPositive Net Change NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study
by Zacks Equity Research
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.
PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates
by Zacks Equity Research
bluebird bio (BLUE) revenues miss the Zacks Consensus Estimate in the fourth quarter. The company progresses with the launch of its three approved gene therapies.
VRTXNegative Net Change HTGCPositive Net Change CRSPPositive Net Change
biotechnology biotechs medical pharmaceuticals
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
by Zacks Equity Research
Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.
NVSPositive Net Change INCYNegative Net Change ADMAPositive Net Change MESOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Praxis (PRAX) Surges on Positive Epilepsy Study Results
by Zacks Equity Research
Praxis (PRAX) reports strong response rates across both study arms in a phase IIa proof of concept study for epilepsy patients with PPR.
ANIPPositive Net Change ADMAPositive Net Change GLPGPositive Net Change PRAXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
by Zacks Equity Research
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.
ACETPositive Net Change ADMAPositive Net Change FGENNegative Net Change STOKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal
by Zacks Equity Research
Data from a late-stage study shows that a five-week treatment with Axsome's (AXSM) experimental narcolepsy drug reduced weekly cataplexy attacks by 83%, compared to 66% for placebo.
JAZZPositive Net Change ANIPPositive Net Change ADMAPositive Net Change AXSMPositive Net Change
biotechs medical
CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug
by Zacks Equity Research
Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.
BIIBPositive Net Change LLYPositive Net Change PRTANegative Net Change ANIPPositive Net Change
biotechs medical pharmaceuticals
Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA
by Zacks Equity Research
Regeneron's (REGN) efforts to expand its oncology portfolio get a hit as the FDA refuses to approve the lymphoma drug odronextamab.
REGNPositive Net Change ANIPPositive Net Change ADMAPositive Net Change GLPGPositive Net Change
biotechnology biotechs medical pharmaceuticals
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
by Zacks Equity Research
AbbVie (ABBV) offers to buy Landos Biopharma (LABP) to boost its portfolio in inflammatory and autoimmune disease drugs.
MRKNegative Net Change ABBVPositive Net Change CEREPositive Net Change
biotechs pharmaceuticals
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
by Zacks Equity Research
Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.
PFENegative Net Change BAYRYPositive Net Change BBIOPositive Net Change
biotechnology biotechs pharmaceuticals
Vertex (VRTX) Continues to Diversify Beyond CF Franchise
by Zacks Equity Research
While CF remains the main area of focus for Vertex Pharmaceuticals (VRTX), it is seeing success in the development of its non-CF pipeline candidates.
VRTXNegative Net Change MRNANegative Net Change CRSPPositive Net Change
biotechs
Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma
by Zacks Equity Research
Lisata's (LSTA) lead investigational product candidate, LSTA1, gets Rare Pediatric Disease Designation for treating osteosarcoma. Stock rises.
VNDAPositive Net Change ANIPPositive Net Change ADMAPositive Net Change LSTANegative Net Change
biotechs
Vertex (VRTX) Kidney Disease Drug to Enter Clinical Development
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) plans to begin a phase I study on VX-407 in autosomal dominant polycystic kidney disease later this month.
VRTXNegative Net Change ADMAPositive Net Change CRSPPositive Net Change MORPositive Net Change
biotechs
Novo Nordisk (NVO) Gets Positive CHMP Opinion for Insulin Icodec
by Zacks Equity Research
Novo Nordisk (NVO) receives a positive opinion from the CHMP for once-weekly basal insulin icodec for the treatment of diabetes in adults.
NVONegative Net Change ANIPPositive Net Change ADMAPositive Net Change GLPGPositive Net Change
biotechnology biotechs pharmaceuticals